The three existing trials look at the medicines' effects on cancer pain and brachial plexus injury - a severe form of nerve-damage pain, as well as general MS pain.
Peter Chepucavage, a consultant at Plexus Consulting and a former SEC lawyer who helped revise short-selling rules earlier this decade, said the SEC is using the 30-day authority to see if the plan works.